Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C

Ann. Oncol.. 2019 Apr;30(4):621-628

Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: a Multicenter Prospective "Proof of Concept" Phase II Study of the French Oculo-Cerebral Lymphoma (LOC) Network and

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C

Ann. Oncol.. 2019 Jan 29;:

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J

Oncologist. 2018 Sep 28;:

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY

Oncologist. 2018 Feb 22;:

Interactions between glioma and pregnancy: insight from a 52-case multicenter series.

Peeters S, Pagès M, Gauchotte G, Miquel C, Cartalat-Carel S, Guillamo JS, Capelle L, Delattre JY, Beauchesne P, Debouverie M, Fontaine D, Jouanneau E, Stecken J, Menei P, De Witte O, Colin P, Frappaz D, Lesimple T, Bauchet L, Lopes M, Bozec L, Moyal E, Deroulers C, Varlet P, Zanello M, Chretien F, Oppenheim C, Duffau H, Taillandier L, Pallud J,

J. Neurosurg.. 2017 Mar;:1-11

A concurrent ultra-fractionated radiation therapy and temozolomide treatment; a promising therapy for newly diagnosed, inoperable glioblastoma.

Beauchesne P, Quillien V, Faure G, Bernier V, Noel G, Quetin P, Gorlia T, Carnin C, Pedeux R

Int J Cancer. 2015 Oct 26

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, Dam-Hieu P, Ghiringhelli F, Colin P, Godard J, Parker F, Dhermain F, Carpentier AF, Frenel JS, Menei P, Bauchet L, Faillot T, Fesneau M, Fontaine D, Motuo-Fotso MJ, Vauleon E, Gaultier C, Le Guerinel C, Gueye EM, Noel G, Desse N, Durando X, Barrascout E, Wager M, Ricard D, Carpiuc I, Delattre JY, Idbaih A

Neurology. 2015 Sep 18. pii: 10.1212/WNL.0000000000002014.

Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.

Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech F, Beauchesne P, Taillandier L

Anticancer Res. 2013 Aug;33(8):3467-74.

Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.

Blonski M, Pallud J, Goze C, Mandonnet E, Rigau V, Bauchet L, Fabbro M, Beauchesne P, Baron MH, Fontaine D, Peruzzi P, Darlix A, Duffau H, Taillandier L

J Neurooncol. 2013 Jun;113(2):267-75

Three-times daily ultrafractionated radiation therapy, a novel and promising regimen for glioblastoma patients.

Beauchesne P

Cancers (Basel). 2013 Sep 25;5(4):1199-211

Letter to the editor: the natural history of extra-cranial metastasis from glioblastoma multiform [J Neurooncol DOI 10.1007/s11060-011-0575-8].

Beauchesne P

J Neurooncol. 2012 Sep;109(3):593-4; author reply 595

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis.

Bihan C, Foscolo S, Boone M, Blonski M, Coutte A, Darlix A, Beauchesne P, Lefranc M, Lorgis V, Taillandier L, Chauffert B

Case Rep Oncol. 2012 Sep;5(3):530-6

Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.

Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, Campello C, Goze C, Rigau V, Moritz-Gasser S, Kerr C, Ruda R, Soffietti R, Bauchet L, Duffau H

J Neurooncol. 2012 Jan;106(2):353-66

Fotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas.

Beauchesne P

Cancers (Basel). 2012 Feb 1;4(1):77-87

Response to intrathecal infusions of Depocyt(R) in secondary diffuse leptomeningeal gliomatosis. A case report.

Beauchesne P, Blonski M, Brissart H

In Vivo. 2011 Nov-Dec;25(6):991-3.

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Gallego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, Mokhtari K, Tanguy ML, Honnorat J, Delattre JY

J Clin Oncol. 2011 Aug 1;29(22):3050-5

Extra-neural metastases of malignant gliomas: myth or reality?

Beauchesne P

Cancers (Basel). 2011 Jan 27;3(1):461-77

Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours.

Beauchesne P

Lancet Oncol. 2010 Sep;11(9):871-9

Interest and nature of the psychological care for patients and close relations in a medical dedicated neuro-oncology unit

Lanfroy R, Busch E, Colmar K, Bremond A, Garat E, Nicole A, Lanoix AS, Beauchesne P, Taillandier L

Psycho-oncologie. 2010 Jun;4(2):72-83

Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

Beauchesne P, Bernier V, Carnin C, Taillandier L, Djabri M, Martin L, Michel X, Maire JP, Khalil T, Kerr C, Gorlia T, Stupp R, Pedeux R

Neuro Oncol. 2010 Jun;12(6):595-602

Dr BEAUCHESNE Patrick

Fiche personne

coordonnées

Territoire

Statut

affiliation

Recherche

Publications

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and

Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: a Multicenter Prospective "Proof of Concept" Phase II Study of the French Oculo-Cerebral Lymphoma (LOC) Network and

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Interactions between glioma and pregnancy: insight from a 52-case multicenter series.

A concurrent ultra-fractionated radiation therapy and temozolomide treatment; a promising therapy for newly diagnosed, inoperable glioblastoma.

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.

Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.

Three-times daily ultrafractionated radiation therapy, a novel and promising regimen for glioblastoma patients.

Letter to the editor: the natural history of extra-cranial metastasis from glioblastoma multiform [J Neurooncol DOI 10.1007/s11060-011-0575-8].

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis.

Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.

Fotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas.

Response to intrathecal infusions of Depocyt(R) in secondary diffuse leptomeningeal gliomatosis. A case report.

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Extra-neural metastases of malignant gliomas: myth or reality?

Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours.

Interest and nature of the psychological care for patients and close relations in a medical dedicated neuro-oncology unit

Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

In Reference to Alexiou et al. (Neuro-Oncology 2008; 10 : 104-105)

Concomitant bone marrow metastasis of a glioblastoma multiforme revealed at the diagnosis.

Imaging malignant gliomas with Tc-99m-MIBI brain single-photon emission computed tomography.